Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice

Richard M Trosch, Vijay P Misra, Pascal Maisonobe, Savary Om, Richard M Trosch, Vijay P Misra, Pascal Maisonobe, Savary Om

Abstract

Introduction: The efficacy and safety of abobotulinumtoxinA in the management of cervical dystonia has been established in randomized, controlled trials that use a selected trial population. In this meta-analysis of observational data, we evaluated the real-life effectiveness of abobotulinumtoxinA as delivered in routine clinical practice.

Methods: Meta-analysis of patient-level data for adult patients with cervical dystonia treated with abobotulinumtoxinA from three prospective, multicenter, observational studies (NCT01314365, NCT00833196 and NCT01753349).

Results: We report data for patients treated with abobotulinumtoxinA over one injection cycle at 181 neurology centers in 35 countries. CD clinical features as assessed by Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total scores (N = 920) significantly reduced by a mean [95%CI] of -12.9 [-13.9, -11.8] points at Week 4 (N = 449) and -3.2 [-3.8, -2.7] points at the end of the injection cycle (N = 890). All three TWSTRS domains (symptom severity, disability and pain) contributed to the overall improvement. Patients were generally content with symptom control at peak effect of the treatment cycle, with 86% reporting overall satisfaction.

Conclusion: Findings from this meta-analysis of observational studies confirm the effectiveness of abobotulinumtoxinA in routine practice. Despite inclusion of a broader population sample, the magnitude of improvements observed is consistent with that seen in the pivotal, randomized controlled trials.

Keywords: Botulinum toxin; Cervical dystonia; Meta-analysis; Observational study.

© 2020 The Authors.

Figures

Fig. 1
Fig. 1
Mean change from baseline in TWSTRS scores, at peak effect (Week 4) and end of cycle. TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale. Data for Week 4 are based on INTEREST IN CD1 and ANCHOR, data for end of cycle are from all three studies.

References

    1. Albanese A., Bhatia K., Bressman S.B., Delong M.R., Fahn S., Fung V.S., Hallett M., Jankovic J., Jinnah H.A., Klein C., Lang A.E., Mink J.W., Teller J.K. Phenomenology and classification of dystonia: a consensus update. Mov. Disord. 2013;28(7):863–873.
    1. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5:864–872.
    1. Poewe W., Deuschl G., Nebe A., Feifel E., Wissel J., Benecke R., Kessler K.R., Ceballos-Baumann A.O., Ohly A., Oertel W., Kunig G. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport German Dystonia Study Group. J. Neurol. Neurosurg. Psychiatry. 1998;64:13–17.
    1. Wissel J., Kanovsky P., Ruzicka E., Bares M., Hortova H., Streitova H., Jech R., Roth J., Brenneis C., Muller J., Schnider P., Auff E., Richardson A., Poewe W. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J. Neurol. 2001;248:1073–1078.
    1. Truong D., Brodsky M., Lew M., Brashear A., Jankovic J., Molho E., Orlova O., Timerbaeva S., Global Dysport Cervical Dystonia Study G Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat. Disord. 2010;16:316–323.
    1. Truong D., Duane D.D., Jankovic J., Singer C., Seeberger L.C., Comella C.L., Lew M.F., Rodnitzky R.L., Danisi F.O., Sutton J.P., Charles P.D., Hauser R.A., Sheean G.L. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov. Disord. 2005;20:783–791.
    1. Simpson D.M., Hallett M., Ashman E.J. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86:1–9.
    1. Poewe W., Burbaud P., Castelnovo G., Jost W.H., Ceballos-Baumann A.O., Banach M., Potulska-Chromik A., Ferreira J.J., Bihari K., Ehler E., Bares M., Dzyak L.A., Belova A.N., Pham E., Liu W.J., Picaut P. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial. Mov. Disord. 2016;31:1649–1657.
    1. Colosimo C., Tiple D., Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox. Res. 2012;22:265–273.
    1. Albanese A., Asmus F., Bhatia K.P., Elia A.E., Elibol B., Filippini G., Gasser T., Krauss J.K., Nardocci N., Newton A., Valls-Sole J. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur. J. Neurol. 2011;18:5–18.
    1. Misra V.P., Trosch R.M., Maisonobe P., Om S. Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studies. J Clin Mov Disord. 2018;5:4.
    1. Trosch R.M., Espay A.J., Truong D., Gil R., Singer C., LeWitt P.A., Lew M.F., Tagliati M., Adler C.H., Chen J.J., Marchese D., Comella C.L. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: the ANCHOR-CD registry. J. Neurol. Sci. 2017;376:84–90.
    1. Misra V.P., Ehler E., Zakine B., Maisonobe P., Simonetta-Moreau M. Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open. 2012;2
    1. Misra V.P., Colosimo C., Charles D., Chung T.M., Maisonobe P., Om S., group IICs INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. J. Neurol. 2018;265:402–409.
    1. Colosimo C., Charles D., Misra V.P., Maisonobe P., Om S., group IICs How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study. J. Neurol. 2019;266:3038–3046.
    1. Espay A.J., Trosch R., Suarez G., Johnson J., Marchese D., Comella C. Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale. Parkinsonism Relat. Disord. 2018;52:94–97.
    1. Dashtipour K., Mari Z., Jankovic J., Adler C.H., Schwartz M., Brin M.F. Minimal clinically important change in patients with cervical dystonia: results from the CD PROBE study. J. Neurol. Sci. 2019;405:116413.
    1. Dysport (abobotulinumtoxinA) for Injection, for Intramuscular Use. Full US Prescribing Information 2019. Available at . Last accessed May 2020.
    1. Jankovic J., Adler C.H., Charles D., Comella C., Stacy M., Schwartz M., Manack Adams A., Brin M.F. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE) J. Neurol. Sci. 2015;349:84–93.
    1. Dressler D., Paus S., Seitzinger A., Gebhardt B., Kupsch A. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J. Neurol. Neurosurg. Psychiatry. 2013;84:1014–1019.
    1. Turner-Stokes L., Ashford S., Fheodoroff K., Brashear A., Maisonobe P., Lysandropoulos A., Jacinto J. Time to retreatment with botulinum toxin A in upper limb spasticity management: upper limb international spasticity (ULIS)-III study interim analysis. Toxicon. 2019;156(S1):S110.
    1. Field M., Splevins A., Picaut P., van der Schans M., Langenberg J., Noort D., Foster K. AbobotulinumtoxinA (Dysport), OnabotulinumtoxinA (Botox), and IncobotulinumtoxinA (Xeomin) neurotoxin content and potential implications for duration of response in patients. Toxins (Basel) 2018;10:535.
    1. Ferreira J.J., Comella C., Azoulai M., Pain E., Om S. How do patients with cervical dystonia (CD) experience their botulinum neurotoxinA (BoNT-A) treatment cycle: results from an international online survey. Eur. J. Neurol. 2020;27(Suppl. 1)
    1. Sethi K.D., Rodriguez R., Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J. Med. Econ. 2012;15:419–423.
    1. Wissel J. Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - insights from recent studies. Toxicon. 2018;147:100–106.
    1. Misra V.P., Charles D., Colosimo C., Chung T.M., Maisonobe P., Om S. Impact of injection schedule flexibility on patient satisfaction with botulinum toxin treatment for cervical dystonia. Neurology. 2020;94:998.
    1. Skogseid I.M., Kerty E. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur. J. Neurol. 2005;12:163–170.
    1. Jost W.H., Hefter H., Stenner A., Reichel G. Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy. J. Neural Transm. 2013;120:487–496.
    1. Novak I., Campbell L., Boyce M., Fung V.S. Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur. J. Neurol. 2010;17(Suppl. 2):94–108.
    1. Camargo C.H., Cattai L., Teive H.A. Pain relief in cervical dystonia with botulinum toxin treatment. Toxins. 2015;7:2321–2335.
    1. Lobbezoo F., Tanguay R., Thon M.T., Lavigne G.J. Pain perception in idiopathic cervical dystonia (spasmodic torticollis) Pain. 1996;67:483–491.
    1. Siongco P.R.L., Rosales R.L., Moore A.P., Freynhagen R., Arimura K., Kanovsky P., Kaji R., Fernandez H.H., Dressler D. Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study. J. Neural Transm. 2020;127:935–951.
    1. Charles P.D., Manack Adams A., Davis T., Bradley K., Schwartz M., Brin M.F., Patel A.T. Neck pain and cervical dystonia: treatment outcomes from CD PROBE (cervical dystonia patient registry for observation of OnabotulinumtoxinA efficacy) Pain Pract. 2016;16:1073–1082.
    1. Fernandez H.H., Pagan F., Danisi F., Greeley D., Jankovic J., Verma A., Sethi K., Pappert E.J., Group XCS Prospective study evaluating IncobotulinumtoxinA for cervical dystonia or blepharospasm: interim results from the first 145 subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y) 2013;3 tre-03-139-2924-1.
    1. Albanese A, Abbruzzese G, Dressler D, Duzynski W, Khatkova S, Marti MJ, Mir P, Montecucco C, Moro E, Pinter M, Relja M, Roze E, Skogseid IM, Timerbaeva S, Tzoulis C (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J. Neurol. 262, 3301–2213.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere